Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 11 | 2025 | 827 | 2.410 |
Why?
|
| Receptor, ErbB-2 | 9 | 2025 | 514 | 2.180 |
Why?
|
| T-Lymphocytes | 15 | 2025 | 1709 | 2.140 |
Why?
|
| Glioblastoma | 8 | 2018 | 327 | 1.550 |
Why?
|
| Immunotherapy | 7 | 2021 | 670 | 1.040 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 4 | 2018 | 20 | 0.890 |
Why?
|
| Antigens, Neoplasm | 4 | 2020 | 386 | 0.880 |
Why?
|
| Brain Neoplasms | 7 | 2020 | 1207 | 0.880 |
Why?
|
| Sarcoma | 2 | 2024 | 183 | 0.860 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2020 | 482 | 0.860 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 20 | 0.690 |
Why?
|
| Cancer Vaccines | 3 | 2020 | 177 | 0.660 |
Why?
|
| Tumor Escape | 2 | 2016 | 61 | 0.620 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 191 | 0.560 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2017 | 158 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1140 | 0.530 |
Why?
|
| Adoptive Transfer | 2 | 2014 | 237 | 0.490 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 196 | 0.380 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2023 | 1198 | 0.360 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 3339 | 0.350 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 284 | 0.340 |
Why?
|
| Lymphocyte Activation | 2 | 2025 | 692 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1018 | 0.300 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 123 | 0.280 |
Why?
|
| Transplantation Conditioning | 2 | 2018 | 324 | 0.250 |
Why?
|
| Mice, SCID | 3 | 2018 | 568 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2020 | 882 | 0.240 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 418 | 0.240 |
Why?
|
| Immunological Synapses | 1 | 2025 | 26 | 0.240 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 59 | 0.230 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 104 | 0.220 |
Why?
|
| Vidarabine | 1 | 2024 | 80 | 0.220 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 114 | 0.220 |
Why?
|
| Neoplasms | 3 | 2025 | 2772 | 0.220 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 122 | 0.220 |
Why?
|
| Humans | 29 | 2025 | 124618 | 0.220 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 47 | 0.200 |
Why?
|
| Mice | 8 | 2025 | 17639 | 0.200 |
Why?
|
| Antigens, CD19 | 2 | 2021 | 178 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 325 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 1062 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2024 | 12324 | 0.180 |
Why?
|
| Lymphoma | 1 | 2024 | 322 | 0.180 |
Why?
|
| Leukemia | 1 | 2024 | 369 | 0.180 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 58 | 0.170 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 26 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 94 | 0.170 |
Why?
|
| Immunologic Memory | 1 | 2021 | 188 | 0.170 |
Why?
|
| Child | 13 | 2025 | 24374 | 0.170 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 298 | 0.160 |
Why?
|
| Remission Induction | 1 | 2020 | 300 | 0.160 |
Why?
|
| Animals | 9 | 2025 | 34088 | 0.160 |
Why?
|
| Transgenes | 2 | 2020 | 334 | 0.160 |
Why?
|
| Osteosarcoma | 2 | 2019 | 253 | 0.160 |
Why?
|
| Ependymoma | 1 | 2020 | 125 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 324 | 0.150 |
Why?
|
| Epigenomics | 1 | 2019 | 163 | 0.150 |
Why?
|
| Receptor, EphA2 | 1 | 2018 | 29 | 0.150 |
Why?
|
| Antigenic Variation | 1 | 2018 | 39 | 0.150 |
Why?
|
| Alemtuzumab | 1 | 2018 | 88 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 23 | 0.140 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 66 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2020 | 325 | 0.130 |
Why?
|
| Biopsy | 1 | 2020 | 1237 | 0.130 |
Why?
|
| Male | 12 | 2025 | 61200 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 490 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2024 | 6135 | 0.130 |
Why?
|
| Protein Binding | 2 | 2020 | 1738 | 0.130 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 662 | 0.130 |
Why?
|
| Interleukin-13 | 1 | 2016 | 97 | 0.130 |
Why?
|
| Protein Multimerization | 1 | 2016 | 128 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 666 | 0.130 |
Why?
|
| HEK293 Cells | 2 | 2020 | 744 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 251 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 374 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2015 | 797 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 469 | 0.120 |
Why?
|
| Microspheres | 1 | 2015 | 70 | 0.120 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 58 | 0.120 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 109 | 0.120 |
Why?
|
| Child, Preschool | 8 | 2025 | 14009 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 235 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2015 | 330 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2025 | 5145 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1022 | 0.110 |
Why?
|
| Adult | 7 | 2024 | 29440 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2015 | 402 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 669 | 0.110 |
Why?
|
| Female | 12 | 2025 | 66495 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 1947 | 0.100 |
Why?
|
| Aged | 4 | 2024 | 19703 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2025 | 263 | 0.090 |
Why?
|
| Genomics | 1 | 2019 | 1503 | 0.090 |
Why?
|
| Adolescent | 8 | 2025 | 19278 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 780 | 0.090 |
Why?
|
| Infant | 6 | 2025 | 12468 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 419 | 0.090 |
Why?
|
| Middle Aged | 4 | 2024 | 26714 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 767 | 0.090 |
Why?
|
| Antigens, Viral | 1 | 2012 | 439 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1232 | 0.080 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 270 | 0.080 |
Why?
|
| Models, Biological | 1 | 2013 | 1459 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1645 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2025 | 16317 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1660 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 665 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 25 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1163 | 0.060 |
Why?
|
| CD28 Antigens | 1 | 2025 | 79 | 0.060 |
Why?
|
| Busulfan | 1 | 2023 | 44 | 0.050 |
Why?
|
| Survival Rate | 2 | 2017 | 2044 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 200 | 0.050 |
Why?
|
| Prognosis | 2 | 2025 | 4625 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 221 | 0.050 |
Why?
|
| Apoptosis | 2 | 2018 | 1789 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2287 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 63 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 205 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 196 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 337 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 290 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 186 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 187 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 575 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 396 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 28 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 28 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 41 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2018 | 82 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 285 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 275 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 192 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 267 | 0.030 |
Why?
|
| Mutation | 2 | 2021 | 5826 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1089 | 0.030 |
Why?
|
| Young Adult | 2 | 2024 | 9014 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 273 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8191 | 0.030 |
Why?
|
| Polystyrenes | 1 | 2015 | 12 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 500 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 869 | 0.030 |
Why?
|
| Color | 1 | 2015 | 31 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 11 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1562 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 723 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 158 | 0.030 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2014 | 6 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 606 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2393 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 676 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1291 | 0.030 |
Why?
|
| Leukocytes | 1 | 2015 | 205 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 261 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 107 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 373 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 299 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 393 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2025 | 4505 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1032 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1420 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 227 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 470 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3063 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3281 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1390 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3138 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 822 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 218 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1485 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4352 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2091 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1895 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 4795 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3554 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 10270 | 0.010 |
Why?
|